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Role of hypoxia in the pathogenesis of renal disease. The kidney
shows a remarkable discrepancy between blood supply and oxy-
genation. Despite high blood flow and oxygen delivery, oxygen
tensions in the kidney are comparatively low, in particular in the
renal medulla. The reason for this lies in the parallel arrange-
ment of arterial and venous preglomerular and postglomerular
vessels, which allows oxygen to pass from arterioles into the
postcapillary venous system via shunt diffusion. The limitation
in renal tissue oxygen supply renders the kidney susceptible to
hypoxia and has long been recognized as an important factor in
the pathogenesis of acute renal injury. In recent years, evidence
has accumulated that hypoxia does also play a significant role
in the pathogenesis and progression of chronic renal disease,
because different types of kidney disease are usually associated
with a rarefication of postglomerular capillaries. In both acute
and chonic diseases, tissue hypoxia does not only imply the risk
of energy deprivation but also induces regulatory mechanisms
and has a profound influence on gene expression. In particu-
lar, the transcription factor hypoxia inducible factor (HIF) is
involved in cellular regulation of angiogenesis, vasotone, glu-
cose metabolism, and cell death and survival decisions. HIF has
been shown to be activated in renal disease and presumably
plays a major role in protective responses to oxygen depriva-
tion. Recent insights into the regulation of HIF increase our
understanding of the role of hypoxia in disease progression and
open new options to improve hypoxia tolerance and to induce
nephroprotection.
Oxygenation of the kidney is characterized by a re-
markable paradox. On the one hand, in relation to their
weight, the kidneys are the very best perfused organs
of the organism, receiving an overall oxygen supply of
more than 80 mL/min × 100 g weight, of which less than
10% is consumed during its passage through the kidneys
[1]. On the other hand, tissue oxygen tensions in the re-
nal parenchyma are lower than in most other organs and
much below those measured in the renal vein [2]. In par-
ticular, the renal medulla is considered one of the sites
in the body with the lowest oxygen tensions. The expla-
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nation for the discrepancy between high oxygen supply
and low tissue oxygen tensions of the kidney lies in the
unique architecture of the renal vasculature. In both the
cortex and the medulla, branches of the renal arteries and
veins run strictly parallel and in close contact with each
other over long distances. This parallel arrangement al-
lows oxygen to diffuse from the arterial system into the
venous system before it has entered the capillary bed [3,
4]. Thus oxygen is subjected to a countercurrent exchange
comparable with urea, and this mechanism is particularly
relevant in the renal medulla, where it leads to oxygen
tensions below 10 mm Hg [2]. However, the countercur-
rent exchange of oxygen also occurs in preglomerular
arteries of the renal cortex, where oxygen tensions are
about 30 mm Hg with marked variability [2, 4].
At the same time, most tubular segments have a very
limited capacity for anaerobic energy generation and are
thus dependent on oxygen to maintain active transtubular
reabsorption of solutes, in particular sodium. The combi-
nation of limited tissue oxygen supply and high oxygen
demand is considered the main reason for the suscepti-
bility of the kidney to acute ischemic injury [5].
In recent years, increasing evidence has accumulated,
indicating that a reduction in renal oxygen tensions also
plays an important role in the progression of chronic
kidney disease [6]. The impact of hypoxia, respectively
ischemia, on the progression of renal disease can be sum-
marized through three main points. First, it has become
clear that the peritubular capillary bed in the kidney,
which provides the structural basis for adequate oxygen
delivery to tubular cells, is a rather dynamic structure and
that chronic diseases of the kidney are associated with
a rapid decline in capillary density. Second, as a conse-
quence of capillary loss and capillary hypoperfusion, tis-
sue oxygen tensions usually decline in a diseased kidney
(Fig. 1; Table 1). Third, low oxygen tensions may not only
impair energy generation but act as a regulator of cellular
functions and as a specific stimulus for the induction of
certain genes. Altogether, these findings suggest that hy-
poxia is an important factor in the progression of kidney
disease. Unravelling the underlying molecular and cellu-
lar mechanisms is likely to increase our understanding of
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Fig. 1. Schematic presentation of peritubu-
lar capillary perfusion in health and disease.
While the amount of filtered sodium is the
main determinant of renal oxygen consump-
tion, the flow through capillaries arising from
the glomerular vasa efferentia determines
oxygen supply. When glomerular desease
impairs glomerular perfusion, this will auto-
matically impair peritubular perfusion. In ad-
dition, loss of peritubular capillaries impairs
peritubular perfusion and increases diffusion
distances. In contrast, glomeruli undergoing
compensatory hypertrophy will be associated
with an increase in glomerular and peritubular
perfusion, which might also cause microvascu-
lar damage.




-Loss of peritubular capillaries
-Impaired peritubular blood flow due to glomerular hypoperfusion
and/or an imbalance of vasoactive substances
-Increased diffusion barriers due to tubulointerstitial fibrosis




Approximately 10 years ago, Bohle and coworkers
observed in human renal biopsies that the number of
peritubular capillaries declines with progressive loss of
renal function [7]. More recently, a loss of peritubular
capillaries has been reproduced in different animal mod-
els, including experimental glomerulonephritis [8], the
remnant kidney model [9], ureteral obstruction [10], is-
chemia/reperfusion [11], and renal artery stenosis [12].
Interestingly, the decline in capillary density occurs
rapidly within days after the initial insult and persists
for weeks, in parallel with an increase in peritubular ma-
trix deposition. There is evidence for programmed cell
death of endothelial cells by apoptosis [8] and for an im-
balance of angiogenesis regulators, with decreased ex-
pression of pro-angiogenic molecules, such as vascular
endothelial growth factor, and induction of anti-angio-
genic molecules, such as thrombospondin [9, 13–15].
Moreover, the comparison of different mouse strains re-
vealed that genetic predisposition plays an important role
in the effect of nephron loss on capillary density [16].
However, the initial signals that trigger the regressive
response of the vasculature in different disease models
remain to be elucidated. Obviously inflammatory media-
tors and oxidative stress [12] could play an important role,
but hemodynamic factors may also be relevant. A unique
feature of renal oxygenation is the tight link between the
glomerular filtration rate, the main determinant of re-
nal function and peritubular oxygen supply. Because per-
itubular capillaries are derived from the vasa efferentia of
the glomeruli, any disturbance of glomerular blood flow
resulting from glomerular capillary obstruction or scle-
rosis will automatically impair peritubular perfusion. In
addition, a compensatory increase in perfusion of other
glomeruli may increase flow and pressure in the peritubu-
lar capillary network and thereby cause microvascular
injury, which induces capillary regression.
Regardless of what the precise mechanisms may be,
Kang and coworkers have demonstrated the functional
significance of the regression of the capillary network.
They showed that endothelial proliferation induced by
vascular endothelial growth factor treatment in the rat
remnant kidney model results in improved renal function
and lower mortality rates [17].
EVIDENCE FOR TISSUE HYPOXIA IN CHRONIC
KIDNEY DISEASE
A priori it is unclear whether impaired renal perfusion
affects tissue oxygenation. Because glomerular perfusion
determines both oxygen supply (through peritubular cap-
illaries) and oxygen consumption (which is directly re-
lated to the filtered and reabsorbed sodium load), the
effect of changes in glomerular perfusion on the net bal-
ance of renal oxygen tensions is difficult to predict. In fact,
renal artery stenosis was shown to be an infrequent and
mild stimulus for erythropoietin (EPO) formation, which
is normally produced in inverse relationship to peritubu-
lar cortical oxygen tension [18].
Unfortunately, very limited data are available about
the profiles of oxygen tensions in kidneys with different
forms of chronic disease. Several investigators used im-
munostaining techniques with the bioreductive agent pi-
monidazole, which is known to accumulate in hypoxic
tissues and has been used as a radiosensitizer to treat
malignant tumors [19]. They reported increased staining
in an experimental glomerulonephritis model [20], puro-
mycin aminonucleoside nephropathy [21], the remnant
















Fig. 2. Schematic view of hypoxia-responsive
gene expression mediated by HIF. HIF is
a heterodimer, composed of an oxygen-
regulated a-subunit (HIF-1a or HIF-2a) and
a constitutive b-subunit. In the presence of
oxygen-specific prolyl residues of HIFa are
hydroxylated, and hydroxylated HIF can then
bind to an ubiquitin-ligase complex, which tar-
gets HIF for destruction through the ubiq-
uitin proteasome pathway. When insufficient
oxygen is available for the hydroxylation re-
actions (i.e., hypoxia), HIFa does not enter
the destruction pathway and, together with
its constitutive partner HIFb , can bind to
hypoxia-response elements in genes that are
inducible under hypoxic conditions. An addi-
tional hydroxylation reaction regulates HIF
transcriptional activity (not shown).
kidney model [21, 22], as well as in an ischemia/reper-
fusion injury model several weeks after recovery [23].
Careful analysis of the time course of changes in a pro-
gressive model of rat glomerulonephritis suggested that
hypoperfusion of peritubular capillaries induces chronic
hypoxia before progression of tubulointerstitial fibrosis
[20].
A limitation of the use of pimonidazole is that im-
munohistochemistry needed to visualize binding of the
dye is a non-quantitative method, and that the relation-
ship between the staining intensity and tissue oxygen
tensions may be altered by factors that are difficult to con-
trol. Noteworthy, a single study, in which oxygen tensions
were actually measured in the remnant kidney model us-
ing oxygen electrodes, showed higher rather than lower
oxygen tensions in the diseased kidneys [24]. The authors
suggested that this increase in renal oxygenation explains
an “inadequately” low erythropoietin production despite
moderate anemia, which occurs in this model.
Considering these different findings, it appears likely
that changes in renal oxygen tensions in chronic kidney
disease are not uniform, but depend, for example, on the
type of renal disease, the time course of injury, and its
progression. Additional recordings of tissue oxygen ten-
sions in various models to verify such influences would
certainly be desirable. In addition, information about
oxygen tensions in human kidneys would also be of signif-
icant interest. Blood oxygen level–dependent magnetic
resonance imaging has been introduced as a technique
that can be used in humans to visualize changes in renal
oxygenation [25]. Blood oxygen level –dependent mag-
netic resonance imaging has been used to demonstrate
changes in oxygenation in an animal model of diabetic
nephropathy [26], but has not yet been systematically ap-
plied to patients with chronic kidney disease.
HYPOXIA INDUCIBLE FACTOR EXPRESSION
AND THE EFFECTS OF LOW OXYGEN
TENSIONS ON RENAL CELL FUNCTION
Unless oxygen supply is insufficient for the generation
of adenosine triphosphate, the actual level of cellular oxy-
gen tensions has long not been considered to be an impor-
tant variable. In recent years, however, this paradigm was
completely revised. It has become clear that variations in
oxygen tensions continuously regulate many aspects of
cellular functions.
An important aspect of this adaptation is oxygen-
dependent gene regulation mediated by the hypoxia-
inducible transcription factors (HIF). HIFs are
heterodimers of an oxygen- regulated a-subunit and a
constitutive b-subunit. Two isoforms of the a-subunit
have been in the focus of interest, which are structurally
related and regulated in a similar fashion (Fig. 2).
Under normoxic, baseline conditions, we have not de-
tected these transcription factors in any region of the
kidney, despite the chronically low oxygen tensions, in
particular in the renal medulla [27]. Exposing animals
to systemic hypoxia, however, revealed a marked capac-
ity of virtually all renal cells to induce a transcriptional
response through HIF-activation. Interestingly, HIF-1a
and HIF-2a are differentially expressed. HIF-1a accumu-
lates in tubular epithelial cells of most nephron segments,
while the expression HIF-2a is found in peritubular en-
dothelial cells and fibroblasts as well as in glomerular cells
[27]. Acute renal hypoxia due to ischemia/reperfusion
[21, 27], renal infarction [28], or radiocontrast application
[29] (Fig. 3) also induces HIF. Data on HIF expression
in chronic renal disease are yet limited. To circumvent
the technical problems of directly visualizing HIF, which
is rapidly degraded on reoxygenation, and to obtain ad-
ditional evidence for its functional significance, Tanaka
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Fig. 3. Follow-up sections of the outer medulla in a rat kidney model of
radiocontrast nephropathy [29] stained for the bioreductive marker pi-
monidazole (upper panel) and for HIF-1a (lower panel). Note marked
accumulation of HIF-1a in tubules in the immediate vicinity of tubules
that stain most strongly for pimonidazole (arrows). These findings sug-
gest that HIF accumulates in hypoxic cells, but that the ability to induce
HIF declines under very severe hypoxia.
and coworkers have recently generated transgenic rats
expressing a reporter gene driven by the HIF DNA-
binding site, the “hypoxia response element.” Using two
different models, puromycin aminonucleoside nephropa-
thy and the remnant kidney model, they found transgene
activation and thus indirect evidence for induction of the
HIF pathway [21].
HIF is considered a master regulator of gene expres-
sion in response to hypoxia. Its target genes include ery-
thropoietin, angiogenic growth factors, heme-oxygenase
1, glucose transporter 1, and almost all glycolytic enzymes
[30]. In addition, HIF target genes are also involved in cell
survival decisions, including apoptosis, and both pro- and
antiapoptotic effects have been described [31, 32]. The
majority of cellular effects of HIF induction are likely to
confer adaptation and protection against hypoxic injury,
and HIF induction is therefore a potential strategy for
nephroprotection (see below). On the other hand, un-
der certain circumstances, genes induced by hypoxia may
also be maladaptive and, in particular, may promote re-
nal fibrosis. Thus, hypoxia was found to induce collagen
messenger RNA expression and induce tissue inhibitors
Table 2. Theoretical options to reduce renal tissue hypoxia or
improve hypoxia-adaptation
-Increasing renal oxygen delivery, for example, by increasing the
hemogloblin concentration
-Percutaneous transluminal angioplasty or surgical revascularization
procedures
-Improving microvascular density by stimulating angiogenesis or
avoiding capillary regression
-Improving the regional balance between oxygen delivery and
consumption, for example, by inhibiting the renin angiotensin
system
-Antifibrotic strategies
-Activating HIF, for example, by prolyl hydroxylase inhibitors
of metalloproteinases [33]. Transforming growth factor b
can be directly induced by hypoxia [34] and, in addition,
Ctgf, a downstream mediator of profibrotic cytokines, in-
cluding transforming growth factor b , can be induced by
hypoxia through HIF activation [35]. Hypoxia also pro-
motes the transdifferentiation of proximal tubular cells
into myofibroblasts [33, 36].
Another aspect in how hypoxia may indirectly promote
renal injury is an increase in blood pressure. Exposure
of rats to systemic hypoxia leads to a significant rise in
blood pressure that persists after return-to-normal am-
bient oxygen tensions [37]. This rise is associated with
microvascular endothelial changes, subtle tubulointersti-
tial injury, inflammation, and interstitial cell prolifera-
tion. Johnson et al have postulated such microvascular
changes as a uniform pathway for the development of
salt-sensitive hypertension [38].
An additional role of hypoxia may be its effect on main-
tenance and recruitment of adult renal stem cells. A re-
cent report indicates that the renal medulla serves as a
niche for adult renal stem cells, which resume prolifera-
tion and are recruited into different zones of the kidney
after tubular damage [39]. Hypoxia modulates the phe-
notype of isolated papillary cells [39], and HIF is believed
to play a central role in stem cell responses in different
organs [40, 41].
TARGETING RENAL HYPOXIA AS A
THERAPEUTIC AIM
Given the increasing, albeit yet fragmentary, evidence
for an important role of hypoxia in the pathogenesis and
progression of renal disease, attempts to avoid a reduc-
tion in renal tissue oxygen tensions and/or manipulating
and supporting the adaptive reactions could help to pre-
serve renal structure and function (Table 2).
In general, improving renal oxygenation could be
achieved by enhancing systemic oxygen transport or re-
gional oxygen supply. The question as to whether correct-
ing renal anemia with recombinant EPO has an impact on
the progression of renal disease is still under debate (see
also Rossert et al, this issue). Although the majority of
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investigations performed so far have not revealed a rele-
vant beneficial or adverse effect of anemia correction on
the decline of glomerular filtration rate, a recent study
suggested that anemia correction may retard the time to
dialysis in patients with advanced chronic kidney disease
[42].
Improving regional oxygen supply in the kidney inde-
pendent of blood oxygen transport capacity could hypo-
thetically be achieved with angiogenesis stimulators that
promote peritubular capillary formation. Although such
approaches have been successful in experimental models,
as discussed, the complexity of angiogenesis modulation
does not seem to render this approach realistic in the near
future.
On the other hand, some of the beneficial effects of
inhibiting the renin angiotensin system could be due to
an improvement of renal oxygenation. Relieving efferent
arteriolar tone by angiotensin II inhibition will reduce the
filtered load and increase peritubular perfusion, thereby
increasing the ratio between oxygen supply and de-
mand. Indeed renin-angiotensin-aldosterone system in-
hibition increases renal cortical oxygen tensions acutely
[43] and ameliorates tubular hypoxia in the remnant
kidney model [22]. In humans this mechanism has been
indirectly observed as an inhibitory effect of angiotensin-
converting enzyme inhibitors or angiotensin receptor an-
tagonists on EPO production and hemoglobin levels [44].
However, the extent to which the protective effect of
renin-angiotensin-aldosterone system inhibition can be
attributed to improved renal oxygenation remains un-
clear.
The use of EPO also has to be considered among strate-
gies aiming to induce tissue- and cytoprotection. There is
increasing evidence that in addition to its main effect as
a growth and survival factor of red cell precursors, EPO
has paracrine effects mediated through EPO receptors
in various organs that confer protection against hypoxic
injury [45]. In fact, cell and tissue protection, indepen-
dent of hemoglobin levels, has been demonstrated in
isolated renal cells [46], as well as in the ischemia reperfu-
sion model [47, 48] and in models of chronic renal injury
[49]. Whether these findings are of any relevance under
the conditions of EPO therapy usually applied for ane-
mia correction in patients with chronic kidney disease,
however, remains to be determined. In fact, increasing
hemoglobin levels with EPO therapy is likely to down-
regulate residual endogenous EPO production, so that
the local EPO concentration could theoretically even de-
crease under exogenous hormone therapy.
Increased recognition of the molecular mechanisms
regulating HIF has recently opened new options for hy-
poxia protection that are independent of the delivery of
a specific gene product. In the presence of oxygen, the
a-subunits of HIF (HIF-1a and HIF-2a) are rapidly de-
graded through the ubiquitin proteasome pathway. This
degradation is initiated by the hydroxylation of two prolyl
residues of HIFa, which requires oxygen as a substrate.
Only hydroxylated HIF can bind to an ubiquitin-ligase
complex, which targets HIF for proteasomal destruction
[50, 51]. As a consequence, inhibitors of the prolyl hy-
droxylases, those enzymes which hydroxylate HIF, inhibit
HIF degradation and mimic the effect of hypoxia in the
presence of oxygen [50, 52]. Such inhibitors have been
found to upregulate HIF in the kidney in vivo and induce
angiogenesis in an experimental model [53]. Cobalt chlo-
ride, which can also stimulate HIF by interfering with
its degradation, was shown to confer protection in an
acute renal failure model [54] and a rat glomerulonephri-
tis model [55]. Further proof of the protective effect of
HIF was recently provided in a rat ischemia model in
which gene transfer of a constitutively active HIF con-
ferred medullary protection [56].
Whether similar protective effects can be achieved in
chronic disease models is not yet clear. Interestingly, how-
ever, prolyl hydroxylase inhibitors are already in use in
phase I and II studies in humans [57], and thus this ap-
proach could soon become available for patients for var-
ious indications. It will potentially offer new avenues of
functional preservation of the kidney, and at the same
time help to further clarify the relevance of hypoxia in
kidney disease.
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